Trial Profile
A First-in-Human, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Oral Dose Study to Assess the Safety, Tolerability and Pharmacokinetics of DV-928 in Healthy Volunteers
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 05 Aug 2016
Price :
$35
*
At a glance
- Drugs Larsucosterol (Primary)
- Indications Fatty liver
- Focus Adverse reactions; First in man; Pharmacokinetics
- 30 Mar 2015 Status changed from not yet recruiting to completed as reported in DURECT Corporation media release.
- 31 Oct 2014 New trial record